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Irinotecan and mismatch repair
deficiency
We read the recent publications of Ychou et al. [1, 2] on
‘adjuvant’ irinotecan-based chemotherapy in high-risk localized
colorectal cancer (CRC) and after resection of liver-confined
metastatic disease with great interest. In contrast to the
improved outcome provided by oxaliplatin-based adjuvant
treatment of early-stage disease, there is now a body of evidence
showing that the addition of irinotecan to 5-fluorouracil
(5-FU)/Leucovorin does not provide a benefit in this setting
[1, 3]. The authors are to be congratulated for reporting the
largest randomized trial of adjuvant treatment after resected
colorectal liver metastases. Such trials have been historically
difficult to accrue and it has been hard to show an overall
survival benefit with either systemic or regional treatment in this
setting. On the basis of data, we are now pretty sure that the
conclusion from the localized disease setting—only
combination of 5-FU with oxaliplatin confers an advantage over
5-FU alone—can also be applied to liver-confined resectable
CRC as has already been common practice in most centers.
It is a commonly uttered wish that future clinical trials
should stratify patients according to their particular risk as well
as biomarkers predicting response to treatment. Resectable
metastatic CRC would lend itself to such a strategy as the
postoperative recovery period leaves several weeks to do the
‘molecular homework’. Despite groundbreaking work in colon
cancer assessing the role of topoisomerase I, thymidylate
synthase and excision repair cross-complementation group in
predicting response to irinotecan, 5-FU and oxaliplatin,
respectively, practice-changing trials are still at large. DNA
mismatch repair (MMR) defects, in contrast, are easily assessed
by immunohistochemistry and may provide important
information regarding efficacy of irinotecan [4]. We are
interested to know whether Ychou et al. assessed tumor tissue
for DNA MMR defects or microsatellite instability (MSI).
Patients who can undergo curative resection of liver metastases
have an outcome that lies somewhere between that for patients
with stage IIIB–IIIC disease. MMR status may, therefore, be of
relevance for this group. We acknowledge that MMR loss is an
uncommon event in sporadic advanced CRC (<10%) [5] and
recent data from a large adjuvant trial for early-stage disease
have shown that MSI, a surrogate for MMR protein loss, was
less common in stage III and was not independently prognostic
of outcome (relapse-free survival and overall survival) [6].
However, there are little data on the potential role of MMR loss
as a biomarker post-liver resection and chemotherapy trials in
this setting are lacking. One of the difficulties inherent to
accrual for adjuvant trials is likely explained by the reluctance
of patients and physicians alike to consider a surgery-alone arm
after liver resection. The validation of biomarkers such as MMR
loss, even in small subsets of patients, may make a surgery-
alone arm more attractive, improve accrual and may identify
a population who will benefit most from adjuvant therapy. In
concordance with the authors, we also feel that ‘considerations
for tailoring combination therapies in the adjuvant treatment
of liver-limited CRC to patients who will receive most benefit
will need to be integrated into future trials’. Response to
oxaliplatin-based treatment may also be different in tumors
that harbor MMR defects [7].
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